A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

NCT06238843 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

464

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）
DRUG: IBI343

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.